Medicinal Chemicals & Botanical Products · SIC 2833

MANNATECH INC

MTEX

Watch

Latest revenue

$24.9M

as of 2026-03-31

Latest net income

$950.0K

as of 2026-03-31

Net margin

3.8%

as of 2026-03-31

Price · 5Y

-28.0% / yr 41.7 pts / yr vs S&P 500 80.5% total
Compare:

Live market

delayed ≤15 min
$4.37
1.13%
Market cap
$8.4M
Enterprise value
$8.4M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$12.45
52-wk low
$3.80
Beta
Shares out
1.9M

5-year trend

dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).

What this company does

AI

Item 1. Business Overview Mannatech, Incorporated ("Mannatech" or the "Company") is a global wellness solution provider, which was incorporated and began operations in November 1993. We develop and sell innovative, high quality, proprietary nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. We currently sell our products in three regions: (i) the Americas (the United States, Canada and Mexico); (ii) Europe/the Middle East/Africa (“EMEA”) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden and the United…

AI summary unavailable — showing raw filing excerpt

Generated from MTEX's filing dated 2026-04-15

Key risks

AI

Item 1A. Risk Factors In addition to the other risks described in this report, the risk factors outlined below should be considered in evaluating our business and future prospects. Several of the risks are part of conducting business in the industry and sales channel in which we operate and will likely remain ongoing. The fact that these risks are characteristic of the dietary supplement industry or the direct selling channel does not lessen their significance. The risks outlined below are not the only risks we may encounter. Additional risks not currently known to us or that may currently reasonably seem immaterial also may have an adverse effect on our business. Risks Affecting Our…

AI summary unavailable — showing raw filing excerpt

Generated from MTEX's filing dated 2026-04-15

Profitability

Gross margin

74.9%

3.4%

Operating margin

-0.4%

132.5%

Net margin

-14.1%

766.5%

Return on equity

-176.6%

711.0%

Return on assets

-50.7%

834.5%

Leverage

Debt / equity

2.48×

22.1%

Long-term debt / equity

0.32×

5.2%

Debt / assets

71.3%

6.3%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$24.9M-6.2%$950.0K+162.1%3.8%

Q3 2025

2025-09-30

$29.2M-8.1%$1.9M+743.9%6.6%

Q1 2025

2025-03-31

$26.6M-9.6%$-1.5M-229.7%-5.8%

Q4 2024

2024-12-31

$29.0M$526.0K1.8%

Q3 2024

2024-09-30

$31.7M-2.5%$228.0K+1166.7%0.7%

Q2 2024

2024-06-30

$27.7M-14.9%$556.0K+211.0%2.0%

Q1 2024

2024-03-31

$29.4M$1.2M4.0%

Q3 2023

2023-09-30

$32.6M$18.0K0.1%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Medicinal Chemicals & Botanical Products · SIC 2833

No data yet for industry average

Your notes

Keep private notes on MTEX — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$62.2K

Insider selling

$0

Net activity

+$62.2K

Distinct insiders

2

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-20

Larry A Jobe

Director

Purchase2,803$4.12$11.5K
2026-05-19

Larry A Jobe

Director

Purchase5,000$4.20$21.0K
2026-05-19

Kevin Andrew Robbins

Director

Purchase7,100$4.17$29.6K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns MTEX

Institutional value

$691.3K

Total shares held

124.9K

Distinct holders

10

-9 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1BlackRock, Inc.52.2K$301.5K+0 (+0.0%)No change
2VANGUARD CAPITAL MANAGEMENT LLC49.6K$297.7KNew
3DIMENSIONAL FUND ADVISORS LP11.9K$71.5K-753 (-5.9%)Trimmed
4VANGUARD FIDUCIARY TRUST CO2.7K$16.1KNew
5UBS Group AG485$2.8K+6 (+1.3%)Added
6Vanguard Global Advisers, LLC250$1.5KNew
7SRS Capital Advisors, Inc.12$72+0 (+0.0%)No change
8ACADIAN ASSET MANAGEMENT LLC7.7K$46+0 (+0.0%)No change
9SBI Securities Co., Ltd.1$6-1 (-50.0%)Trimmed
10WELLS FARGO & COMPANY/MN1$4-1 (-50.0%)Trimmed

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once MTEX's latest filing finishes processing.